Adaptimmune Therapeutics PLCADAP

時価総額

PER

	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日
Revenue	14	38	60	1	4	6	27
Research and development	64	87	98	98	92	111	128
General and administrative	23	31	44	43	46	57	63
Total operating expenses	87	118	142	141	137	168	191
Operating loss	-73	-81	-82	-140	-133	-162	-164
Interest income	-	-	-	-	2	1	2
Other income (expense), net	1	9	-16	0	1	4	-1
Loss before income tax expense	-71	-70	-95	-137	-130	-157	-163
Other income (expense), net	1	9	-16	0	1	4	-1
Income tax expense	1	0	0	0	0	1	2
Loss before income tax expense	-71	-70	-95	-137	-130	-157	-163
Net loss attributable to ordinary shareholders	-72	-70	-96	-137	-130	-158	-165
Income tax expense	1	0	0	0	0	1	2
Basic (in dollars per share)	-	-	-	-	-	-0.17	-0.17
Diluted (in dollars per share)	-	-	-	-	-	-0.17	-0.17
Net loss attributable to ordinary shareholders	-72	-70	-96	-137	-130	-158	-165
Basic (in dollars per share)	-	-	-	-	-	-0.17	-0.17
Diluted (in dollars per share)	-	-	-	-	-	-0.17	-0.17